argenx SE 2022 SR
The report highlights argenx's transition into a fully integrated global commercial organization, reaching over 3,000 patients with its first-in-class treatment, VYVGART. The company emphasizes its commitment to immunology innovation through its Immunology Innovation Program and co-creation model. Key achievements in 2022 include diversifying the Board of Directors to 33% female representation and maintaining a zero-accident workplace for the third consecutive year. Environmentally, the company began measuring its footprint, reporting over 50% renewable energy use at its Ghent site and implementing sustainable waste management practices.
Company: argenx SE
Sector: Manufacturing
Country: Netherlands
Year: 2022
Type: SR
Pages: 48
Back to company
argenx SE
ESG Report
The report highlights argenx's transition into a fully integrated global commercial organization, reaching over 3,000 patients with its first-in-class treatment, VYVGART. The company emphasizes its commitment to immunology innovation through its Immunology Innovation Program and co-creation model. Key achievements in 2022 include diversifying the Board of Directors to 33% female representation and maintaining a zero-accident workplace for the third consecutive year. Environmentally, the company began measuring its footprint, reporting over 50% renewable energy use at its Ghent site and implementing sustainable waste management practices.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Renewable Energy
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees